The World Health Organization (WHO) has recommended the use of Regeneron synthetic antibody treatment for COVID-19 in patients with some specific health profiles.

Individuals who have non-severe COVID-19 and are still at high risk of hospitalization can be given the antibody combination. It can also be administered to severely ill patients who are not able to mount an adequate immune response. The findings are published in the BMJ.

Regeneron is a combination of synthetic antibodies casirivimab and imdevimab and has been noted to decrease the risk of hospital admission for unvaccinated individuals, elderly or immunosuppressed patients with COVID-19, as per the findings of three clinical trials yet to be peer reviewed, reported the BMJ… (NDTV – AFP, September 24, 2021)